A1A

(redirected from Alpha-1-Antitrypsin)
Also found in: Medical, Encyclopedia.
AcronymDefinition
A1AAlpha-1-Antitrypsin
References in periodicals archive ?
Patents in the portfolio include the production of several recombinant proteins such as Alpha-1-Antitrypsin, Bile Salt Stimulated Lipase, Extracellular Superoxide Dismutase, Alpha-lactalbumin and Factor IX.
Variants of alpha-1-antitrypsin in Puerto Rican children with asthma.
Despite the drawbacks, single- and bilateral-lung transplants and the alpha-1-antitrypsin substance are providing new hope for persons with COPD after careful dialogue between patients, families and their physicians.
Evaluation of an integrative diagnostic algorithm for the identification of people at risk for alpha-1-antitrypsin deficiency.
Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida).
Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, intravenous immune globulin used to prevent infections in people with immune deficiencies and other serious conditions, and alpha-1 proteinase inhibitor used to treat people with alpha-1-antitrypsin deficiency, also known as genetic emphysema.
Alpha-1-antitrypsin deficiency: biochemistry and clinical manifestations [Review].
Severe Alpha-1-Antitrypsin Deficiency, also known as AAT Deficiency or Alpha-1, is an inherited disorder that causes a significant reduction of the serum concentration of the naturally occurring protein AAT.
Amino acid substitution Glu-Lys in alpha-1-antitrypsin PiZ.
Grant programs such as the Talecris Biotherapeutics Alpha-1 Research Initiative and the European Alpha-1-Antitrypsin Laurell's Training Award (eALTA), which support basic and clinical research and education through grants provided to early career investigators, fellows-in-training, and other Alpha-1 health care professionals, are continuing.
Arriva and ProMetic formed a joint venture in 1999 to develop and commercialize recombinant alpha-1-antitrypsin (AAT) and other serine protease inhibitors for the treatment of various inflammatory conditions, including dermatological diseases such as atopic dermatitis and psoriasis.
Infusion of alpha-1-antitrypsin (ATT) to suppress Human Immunodeficiency Virus Type 1 (HIV) replication in patients:
Full browser ?